Patents by Inventor Subhash Desai
Subhash Desai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11923668Abstract: The present disclosure provides a cable tray assembly comprising a cable tray splice, first cable tray section, and second cable tray section adjacent the first cable tray section with both sections having a bottom wall. The cable tray splice couples to the bottom walls. The cable tray splice may include at least two fasteners and a splice body configured to engage adjacent cable tray sections. The fasteners are configured to couple the splice body to the adjacent cable tray sections and include a spring producing a biasing force against the splice body. The disclosure provides a method to form a cable tray assembly including positioning the two cable tray sections end-to-end, positioning a splice body on bottom walls of the two cable tray sections, inserting a fastener through aligned openings in the splice body and the bottom walls, and applying a spring biasing force to the splice body.Type: GrantFiled: May 5, 2022Date of Patent: March 5, 2024Assignee: EATON INTELLIGENT POWER LIMITEDInventors: Jayram Shivajirao Desai, Lalit Subhash Khairnar
-
Publication number: 20230287292Abstract: The present invention provides an engine oil composition including 70 to 95 percent by weight of a base oil and 0.01 to 15 percent by weight of a dispersant comb polymer, based on the overall weight of the engine oil composition. The dispersant comb polymer consists of 13.7% by weight of a macromonomer, which is an ester of methacrylic acid and a hydroxylated hydrogenated polybutadiene with Mn of 4750 g/mol; 51.5% by weight of n-butyl methacrylate; 17.3% by weight of LMA; 11.2% by weight of styrene; 0.2% by weight of methyl methacrylate; and 6.10% by weight of N,N-dimethylaminoethyl methacrylate. The modified dispersant inhibitor package contains 30 wt % or less of succinimide type dispersant based on the overall weight of the modified dispersant inhibitor additive package, and the engine oil composition has an SAE viscosity grade of 0W-X, wherein X is 30 or less.Type: ApplicationFiled: September 1, 2021Publication date: September 14, 2023Inventors: Priyanka Subhash DESAI, Mark Clift SOUTHBY
-
Patent number: 11443014Abstract: The technology disclosed relates to matrix multiplication where the multiplier can be a sparse matrix. In particular, a multiplication device includes first circuitry configured to obtain the multiplicand matrix and an index of columns of the multiplier matrix and to generate an intermediate matrix that has one row per entry in the index copied from a respective row of the multiplicand matrix based on a value of a corresponding entry in the index. The device also includes second circuitry configured to receive the intermediate matrix from the first circuitry, obtain non-zero values of the multiplier matrix and a list of a number of non-zero entries per row of the multiplier matrix, and generate a product matrix as a result of multiplies of the non-zero values of the multiplier matrix and the intermediate matrix.Type: GrantFiled: November 5, 2021Date of Patent: September 13, 2022Assignee: SambaNova Systems, Inc.Inventors: Mingran Wang, Raghu Prabhakar, Darshan Dhimantkumar Gandhi, Maulik Subhash Desai, Nathan Francis Sheeley, Scott Layson Burson, Sitanshu Gupta
-
Patent number: 10912744Abstract: The present invention provides drug therapy formulations for reducing the side effects associated with a therapeutic. In some embodiments, the present invention provides a reduction in sleep- and diet-related side effects associated with a therapeutic.Type: GrantFiled: September 23, 2019Date of Patent: February 9, 2021Assignee: KemPharm, Inc.Inventor: Subhash Desai
-
Publication number: 20200054582Abstract: The present invention provides drug therapy formulations for reducing the side effects associated with a therapeutic. In some embodiments, the present invention provides a reduction in sleep- and diet-related side effects associated with a therapeutic.Type: ApplicationFiled: September 23, 2019Publication date: February 20, 2020Inventor: Subhash Desai
-
Patent number: 10463633Abstract: The present invention provides drug therapy formulations for reducing the side effects associated with a therapeutic. In some embodiments, the present invention provides a reduction in sleep- and diet-related side effects associated with a therapeutic.Type: GrantFiled: April 25, 2011Date of Patent: November 5, 2019Assignee: KemPharm, Inc.Inventor: Subhash Desai
-
Publication number: 20170105983Abstract: The present invention provides drug therapy formulations. In some embodiments, the present invention provides combinations of pharmaceutical agents (e.g., stimulant and non-stimulant), pharmaceutical formulations (e.g., nanoparticualte, non-nanoparticualte, etc.), and release profiles (e.g., immediate release, delayed release, sustained release, etc.) to provide therapeutic benefit with reduced side effects.Type: ApplicationFiled: October 31, 2016Publication date: April 20, 2017Inventor: Subhash Desai
-
Patent number: 9511037Abstract: The present invention provides drug therapy formulations. In some embodiments, the present invention provides combinations of pharmaceutical agents (e.g., stimulant and non-stimulant), pharmaceutical formulations (e.g., nanoparticualte, non-nanoparticualte, etc.), and release profiles (e g, immediate release, delayed release, sustained release, etc.) to provide therapeutic benefit with reduced side effects.Type: GrantFiled: October 19, 2012Date of Patent: December 6, 2016Assignee: GENCO SCIENCES LLCInventor: Subhash Desai
-
Publication number: 20130039960Abstract: The present invention provides drug therapy formulations. In some embodiments, the present invention provides combinations of pharmaceutical agents (e.g., stimulant and non-stimulant), pharmaceutical formulations (e.g., nanoparticulate, non-nanoparticulate, etc.), and release profiles (e.g., immediate release, delayed release, sustained release, etc.) to provide therapeutic benefit with reduced side effects.Type: ApplicationFiled: October 19, 2012Publication date: February 14, 2013Inventor: Subhash Desai
-
Publication number: 20110262496Abstract: The present invention provides drug therapy formulations for reducing the side effects associated with a therapeutic. In some embodiments, the present invention provides a reduction in sleep- and diet-related side effects associated with a therapeutic.Type: ApplicationFiled: April 25, 2011Publication date: October 27, 2011Inventor: Subhash Desai
-
Publication number: 20090149431Abstract: A novel crystalline form (Form L) of the aldosterone receptor antagonist drug eplerenone is provided having relatively high physical stability at normal temperatures of storage and use. Pharmaceutical compositions are also provided comprising Form L eplerenone, optionally accompanied by one or more other solid state forms of eplerenone, in a total unit dosage amount of eplerenone of about 10 to about 1000 mg, and further comprising one or more pharmaceutically acceptable excipients. Processes are provided for preparing Form L eplerenone and for preparing compositions comprising Form L eplerenone. A method for prophylaxis and/or treatment of an aldosterone-mediated condition or disorder is also provided, comprising administering to a subject a therapeutically effective amount of eplerenone, wherein at least a fraction of the eplerenone present is Form L eplerenone.Type: ApplicationFiled: February 18, 2009Publication date: June 11, 2009Inventors: Kathleen P. Barton, Thomas B. Borchardt, Marlow V. Carlos, Subhash Desai, Leonard J. Ferro, Henry T. Gaud, Scott S. Ganser, Clay R. Little, Partha S. Mudipalli, Mark A. Pietz, Daniel R. Pilipauskas, Yuen-Lung L. Sing, Glenn L. Stahl, Joseph J. Wieczorek, Chris Y. Yan
-
Publication number: 20070202170Abstract: Pharmaceutical compositions are provided comprising one or more orally deliverable dose units, each comprising a selective cyclooxygenase-2 inhibitory drug of low water solubility, for example celecoxib, in an immediate-release fraction and a controlled-release, slow-release, programmed-release, timed-release, pulse-release, sustained-release or extended-release fraction. The compositions are useful in treatment or prophylaxis of cyclooxygenase-2 mediated conditions and disorders.Type: ApplicationFiled: May 4, 2007Publication date: August 30, 2007Inventors: Subhash Desai, Sreekant Nadkarni, Randy Wald, Gary DeBrincat
-
Patent number: 7220434Abstract: Pharmaceutical compositions are provided comprising one or more orally deliverable dose units, each comprising a selective cyclooxygenase-2 inhibitory drug of low water solubility, for example celecoxib, in an immediate-release fraction and a controlled-release, slow-release, programmed-release, timed-release, pulse-release, sustained-release or extended-release fraction. The compositions are useful in treatment or prophylaxis of cyclooxygenase-2 mediated conditions and disorders.Type: GrantFiled: December 20, 2000Date of Patent: May 22, 2007Assignee: Pharmacia Corporation (of Pfizer, Inc.)Inventors: Subhash Desai, Sreekant R. Nadkarni, Randy J. Wald, Gary A. DeBrincat
-
Patent number: 7172769Abstract: Pharmaceutical compositions are provided comprising one or more orally deliverable dose units, each comprising a selective cyclooxygenase-2 inhibitory drug of low water solubility in a therapeutically effective amount, wherein the drug is present in the form of solid particle, about 25% to 100% by weight of which are smaller than 1 ?m. The compositions are useful in treatment or prophylaxis of cyclooxygenase-2 mediated conditions and disorders and have particular advantages where rapid onset of therapeutic effect is desired.Type: GrantFiled: December 6, 2000Date of Patent: February 6, 2007Assignee: Pharmacia CorporationInventors: Tugrul T. Kararli, Mark J. Kontny, Subhash Desai, Michael J. Hageman, Royal J. Haskell
-
Publication number: 20050267302Abstract: A novel crystalline form (Form H) of the aldosterone receptor antagonist drug eplerenone is provided having a relatively rapid dissolution rate in aqueous media. Also provided are novel solvated crystalline forms of eplerenone that, when desolvated, can yield Form H eplerenone. Also provided is amorphous eplerenone. Pharmaceutical compositions are provided comprising Form H eplerenone, optionally accompanied by one or more other solid state forms of eplerenone, in a total unit dosage amount of eplerenone of about 10 to about 1000 mg, and further comprising one or more pharmaceutically acceptable excipients. Processes are provided for preparing Form H eplerenone and for preparing compositions comprising Form H eplerenone. A method for prophylaxis and/or treatment of an aldosterone-mediated condition or disorder is also provided, comprising administering to a subject a therapeutically effective amount of eplerenone, wherein at least a fraction of the eplerenone present is Form H eplerenone.Type: ApplicationFiled: December 4, 2003Publication date: December 1, 2005Applicant: G.D. Searle & Co.Inventors: Kathleen Barton, Thomas Borchardt, Marlon Carlos, Subhash Desai, Leonard Ferro, Henry Gaud, Scott Ganser, Clay Little, Partha Mudipalli, Mark Pietz, Daniel Pilipauskas, Yuen-Lung Sing, Glenn Stahl, Joseph Wieczorek, Chris Yan
-
Publication number: 20050261261Abstract: A novel crystalline form (Form L) of the aldosterone receptor antagonist drug eplerenone is provided having relatively high physical stability at normal temperatures of storage and use. Pharmaceutical compositions are also provided comprising Form L eplerenone, optionally accompanied by one or more other solid state forms of eplerenone, in a total unit dosage amount of eplerenone of about 10 to about 1000 mg, and further comprising one or more pharmaceutically acceptable excipients. Processes are provided for preparing Form L eplerenone and for preparing compositions comprising Form L eplerenone. A method for prophylaxis and/or treatment of an aldosterone-mediated condition or disorder is also provided, comprising administering to a subject a therapeutically effective amount of eplerenone, wherein at least a fraction of the eplerenone present is Form L eplerenone.Type: ApplicationFiled: February 7, 2005Publication date: November 24, 2005Applicant: Pharmacia CorporationInventors: Kathleen Barton, Thomas Borchardt, Marlon Carlos, Subhash Desai, Leonard Ferro, Henry Gaud, Scott Ganser, Clay Little, Partha Mudipalli, Mark Pietz, Daniel Pilipauskas, Yuen-Lung Sing, Glenn Stahl, Joseph Wieczorek, Chris Yan
-
Publication number: 20050250748Abstract: Combinations of an ACE inhibitor and an epoxy-steroidal aldosterone receptor antagonist are described for use in treatment of circulatory disorders. Of particular interest are therapies using epoxy-steroidal-type aldosterone receptor antagonist compounds, such as eplerenone, in combination with an angiotensin converting enzyme inhibitor. This co-therapy would be particularly useful to treat congestive heart failure while avoiding or reducing aldosterone-antagonist-induced side effects such as hyperkalemia.Type: ApplicationFiled: August 6, 2003Publication date: November 10, 2005Applicant: G. D. Searle & Co.Inventors: John Alexander, Barbara Roniker, Subhash Desai
-
Publication number: 20050159594Abstract: A novel crystalline form (Form H) of the aldosterone receptor antagonist drug eplerenone is provided having a relatively rapid dissolution rate in aqueous media. Also provided are novel solvated crystalline forms of eplerenone that, when desolvated, can yield Form H eplerenone. Also provided is amorphous eplerenone. Pharmaceutical compositions are provided comprising Form H eplerenone, optionally accompanied by one or more other solid state forms of eplerenone, in a total unit dosage amount of eplerenone of about 10 to about 1000 mg, and further comprising one or more pharmaceutically acceptable excipients. Processes are provided for preparing Form H eplerenone and for preparing compositions comprising Form H eplerenone. A method for prophylaxis and/or treatment of an aldosterone-mediated condition or disorder is also provided, comprising administering to a subject a therapeutically effective amount of eplerenone, wherein at least a fraction of the eplerenone present is Form H eplerenone.Type: ApplicationFiled: July 16, 2004Publication date: July 21, 2005Applicant: Pharmacia CorporationInventors: Kathleen Barton, Thomas Borchardt, Marlon Carlos, Subhash Desai, Leonard Ferro, Henry Gaud, Scott Ganser, Clay Little, Partha Mudipalli, Mark Pietz, Daniel Pilipauskas, Yuen-Lung Sing, Glenn L. Stahl, Joseph Wieczorek, Chris Yan
-
Publication number: 20040265382Abstract: Pharmaceutical compositions are provided comprising one or more orally deliverable dose units, each comprising a selective cyclooxygenase-2 inhibitory drug of low water solubility in a therapeutically effective amount, wherein the drug is present in the form of solid particle, about 25% to 100% by weight of which are smaller tban 1 &mgr;m. The compositions are useful in treatment or prophylaxis of cyclooxygenase-2 mediated conditions and disorders and have particular advantages where rapid onset of therapeutic effect is desired.Type: ApplicationFiled: July 30, 2002Publication date: December 30, 2004Inventors: Tugrul T. Kararli, Mark J. Kontny, Subhash Desai, Michael J. Hageman, Royal J. Haskell
-
Publication number: 20040242640Abstract: Pharmaceutical compositions are provided comprising one or more orally deliverable dose units, each comprising a selective cyclooxygenase-2 inhibitory drug of low water solubility, for example celecoxib, in an immediate-release fraction and a controlled-release, slow-release, programmed-release, timed-release, pulse-release, sustained-release or extended-release fraction. The compositions are useful in treatment or prophylaxis of cyclooxygenase-2 mediated conditions and disorders.Type: ApplicationFiled: February 23, 2004Publication date: December 2, 2004Inventors: Subhash Desai, Sreekant R. Nadkarni, Randy J. Wald, Gary A. DeBrincat